House Unanimously Passes Bills Updating FDA’s Orange and Purple Books

The US House of Representatives on Wednesday unanimously passed two bills that would increase the utility of the US Food and Drug Administration’s (FDA) Orange Book for generic drugmakers and Purple Book for biosimilar developers.